Use of Febuxostat in Hyperuricemia Among Hemodialysis Patients

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03149939

Enrollment

Registered

2017-05-11

Start date

2017-01-01

Completion date

2017-05-01

Last updated

2017-05-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hemodialysis Complication, Hyperuricemia

Brief summary

Hyperuricemia is not infrequently encountered among hemodialysis patients. However, there is no clear data about use of febuxostat among hemodialysis patients, apart from very small case series. The aim of this study is to investigate the efficacy of using febuxostat for the treatment of Hyperuricemia among hemodialysis patients.

Interventions

DRUGFebuxostat 40 milligramsTablet

Febuxostat 40 milligramsTablet every other day for 3 months

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

19 Years to No maximum

Healthy volunteers

Inclusion criteria

* Age above 18 years * Hemodialysis patient * Hyperuricemia (Uric acid level above 6.0 mg/dL in females and 7.0 mg/dL in males)

Exclusion criteria

* Patient currently and/or recently received drugs for hyperuricemia within the last three months * Patient had recent (within 3 months) change of erythropoiesis stimulating drugs or other drug known to increase uric acid e.g furosemide

Design outcomes

Primary

Measure	Time frame	Description
Change in serum uric acid	at three months of Febuxostat 40 milligrams Tablet therapy	Change in serum uric acid after 3 months of Febuxostat 40 milligrams Tablet therapy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026